Scarica l'app Stockscreener
8.505
1.42%
0.12
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Candel Therapeutics reports Phase 2 trial shows extended survival in Pancreatic Cancer - Proactive Investors USA
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha
Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive Investors UK
Candel stock plunges 20% following Phase 2 data release - MSN
Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data -February 25, 2025 at 01:36 pm EST - Marketscreener.com
Candel stock plunges 20% following Phase 2 data release (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Announces Positive Long-Term Survival Data From CAN-2409 Phase 2 Trial - Nasdaq
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy - Proactive Investors USA
Candel Therapeutics stock rises on positive trial data By Investing.com - Investing.com Australia
Candel Therapeutics stock rises on positive trial data - Investing.com
Candel Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Candel Therapeutics Reports Positive Final Survival Data for CAN-2409 in Borderline Resectable Pancreatic Cancer - Nasdaq
Candel Therapeutics Announces Positive Final Survival Data - GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - StockTitan
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week - MSN
(CADL) Trading Report - Stock Traders Daily
Vontobel Holding Ltd. Sells 3,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Citigroup Begins Coverage on Candel Therapeutics (NASDAQ:CADL) - Defense World
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Citi sets $25 target on Candel Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Decline in Short Interest - MarketBeat
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Candel Therapeutics Inc (CADL) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Candel Therapeutics: Entering Its Pivotal Year (NASDAQ:CADL) - Seeking Alpha
Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target -February 20, 2025 at 07:39 am EST - Marketscreener.com
Canaccord Genuity Group Begins Coverage on Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Citigroup Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation - Nasdaq
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice - MSN
Citi sets $25 target on Candel Therapeutics stock with Buy rating - Investing.com India
Candel Therapeutics (NASDAQ:CADL) Now Covered by Analysts at Canaccord Genuity Group - Defense World
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoic - Asianet Newsable
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update - Defense World
Analysts Say Candel Therapeutics Inc (NASDAQ: CADL) Should Remain On Your Watch List - Stocks Register
Trend Tracker for (CADL) - Stock Traders Daily
Insider Sale Alert: Candel Therapeutics Inc [CADL] – Is it Time to sell? - Knox Daily
Candel Therapeutics (NASDAQ:CADL) Coverage Initiated at Bank of America - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns Buy Rating from Analysts at Bank of America - Defense World
Candel Therapeutics Inc (CADL) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Candel Therapeutics Inc (CADL) Stock: Evaluating the Annual Growth - The News Heater
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel initiated at buy by Citi, lead immunotherapy drugs cited - MSN
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
BofA Securities Initiates Candel Therapeutics at Buy With $15 Price Target -February 07, 2025 at 08:39 am EST - Marketscreener.com
B of A Securities Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation - Nasdaq
Nothing is Better Than Candel Therapeutics Inc (CADL) stock at the moment - SETE News
Candel Therapeutics Inc (CADL) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
A closer look at Candel Therapeutics Inc (CADL) is warranted - US Post News
Candel Therapeutics Inc (CADL) rating initates by H.C. Wainwright - Knox Daily
0.38%
2.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):